Type 2 diabetes mellitus (T2DM) and clear cell renal cell carcinoma (ccRCC) are both common diseases that frequently occur together in the same patients. Epidemiological studies have consistently shown that people with T2DM have an elevated risk of developing kidney cancer. However, the biological reasons for this connection have remained poorly understood at the molecular level.
This study used cutting-edge single-cell RNA sequencing (scRNA-seq) to analyze gene activity in individual cells from both T2DM tissue and ccRCC tumors. By examining gene expression at the resolution of single cells, the researchers could identify shared molecular features that might explain why these two diseases occur together.
The central finding was that a gene called LST1 plays a key linking role between T2DM and ccRCC. LST1 is expressed primarily in a type of immune cell called macrophages and is connected to a cellular process called efferocytosis, the immune system's mechanism for cleaning up dead and dying cells.
Understanding this connection opens new avenues for developing biomarkers that identify kidney cancer risk in diabetic patients and for designing treatments that target the shared biological mechanisms underlying both diseases simultaneously.
Efferocytosis is the process by which specialized immune cells, particularly macrophages, engulf and clear apoptotic cells (cells that have undergone programmed cell death). Efficient clearance of dying cells is essential for resolving inflammation and maintaining tissue homeostasis. When efferocytosis is disrupted, dying cells accumulate, triggering chronic inflammation.
Chronic low-grade inflammation is a hallmark of type 2 diabetes. Elevated blood sugar damages tissues and promotes the death of cells throughout the body. If macrophages cannot efficiently clear these dying cells through efferocytosis, the resulting inflammatory environment can promote the development and progression of cancer.
In the tumor microenvironment, efferocytosis by macrophages also has direct consequences for anti-tumor immunity. Macrophages that engulf dead cancer cells and cancer-associated debris can either stimulate an anti-tumor immune response or adopt an immunosuppressive state that protects the tumor. The direction depends in part on the specific molecular machinery controlling the efferocytosis process.
LST1 (Leukocyte Specific Transcript 1) is a membrane protein expressed predominantly in myeloid cells, including monocytes and macrophages. It has been linked to immune regulation and inflammatory signaling, but its specific role in cancer and its connection to diabetes had not previously been investigated in depth.
The researchers began with a bioinformatics approach called weighted gene co-expression network analysis (WGCNA), applied to bulk RNA sequencing data from T2DM and ccRCC datasets. WGCNA identifies groups of genes that are expressed together in coordinated patterns, revealing functional gene modules relevant to each disease.
Genes identified as important in T2DM modules were compared with those important in ccRCC modules to find overlapping candidates. This overlap analysis, combined with additional filtering using differential expression statistics, narrowed the field to genes plausibly involved in both conditions. LST1 emerged from this analysis as a top candidate shared gene.
The team then analyzed single-cell RNA sequencing datasets from ccRCC tumors to identify which cell types expressed LST1. scRNA-seq data was processed using standard pipelines for quality control, dimensionality reduction, and cell type annotation. This step showed that LST1 is specifically and highly expressed in macrophages and monocytes within the tumor microenvironment.
To investigate the role of LST1 in efferocytosis specifically, the researchers analyzed cellular pathways associated with LST1 expression and confirmed its regulatory connection to the MHC-I (major histocompatibility complex class I) antigen presentation pathway. MHC-I molecules are critical for immune cells to recognize and attack abnormal cells, and their regulation by macrophage efferocytosis activity directly links immune clearance to anti-tumor immune responses.
In vivo experiments using mouse models of kidney cancer were performed to validate these computational findings. Mice with reduced LST1 expression in their tumors were compared to control animals to directly measure the effect of LST1 on tumor growth, immune cell infiltration, and efferocytosis efficiency.
LST1 expression was found to be significantly higher in ccRCC tumor tissue compared to adjacent normal kidney tissue, and higher in T2DM-affected tissue compared to healthy tissue. This dual elevation in both diseases provides biological evidence of a shared molecular mechanism and supports the hypothesis that LST1 contributes to the link between diabetes and kidney cancer risk.
Single-cell analysis confirmed that LST1 is predominantly expressed by macrophages infiltrating the tumor. These LST1-high macrophages showed gene expression profiles associated with efferocytosis activity and with an immunosuppressive phenotype, meaning they suppress rather than activate anti-tumor immune responses.
Patients with higher LST1 expression in their tumors showed significantly worse overall and progression-free survival compared to those with lower LST1 expression. Multivariate analysis confirmed that LST1 is an independent prognostic factor, meaning its association with survival is not simply because it correlates with other known prognostic variables like stage or grade.
The association between LST1 and the MHC-I pathway was confirmed at both the gene expression and protein levels. High LST1 macrophages showed reduced activity in genes needed for assembling and presenting MHC-I complexes, suggesting that LST1-expressing macrophages are less effective at alerting cytotoxic T cells to the presence of cancer cells.
To confirm that LST1 plays a functional role in tumor development rather than simply being a bystander marker, the researchers used mouse kidney cancer models in which LST1 expression was reduced using gene silencing approaches. Animals with reduced LST1 in their tumors showed significantly slower tumor growth compared to control animals.
Analysis of the tumor microenvironment in LST1-reduced tumors revealed increased infiltration by cytotoxic CD8+ T cells, the immune cells that kill cancer, and reduced presence of immunosuppressive regulatory T cells and M2 macrophages. This shift toward a more anti-tumor immune landscape is consistent with improved immune recognition when LST1-driven efferocytosis suppression is relieved.
Efferocytosis efficiency itself was also measured in the animal experiments. LST1-deficient macrophages showed reduced capacity to engulf apoptotic cells, confirming that LST1 directly participates in the efferocytosis process. The resulting accumulation of dead cell material in the tumor likely triggered inflammatory signaling that activated rather than suppressed anti-tumor immunity.
These in vivo results provide strong evidence that LST1 is not just a marker but a driver of the immunosuppressive environment in kidney cancer. Targeting LST1 or its downstream pathways could therefore represent a viable strategy for improving immune responses in ccRCC, particularly in diabetic patients where LST1 activity may be additionally elevated.
For the large population of patients who have both type 2 diabetes and kidney cancer, this research offers a potential explanation for their shared biological risk and a candidate biomarker to guide clinical decisions. Measuring LST1 expression in tumor biopsies could eventually help identify which patients have the most immunosuppressive microenvironments and therefore the greatest need for therapies that counteract this suppression.
The findings also raise the question of whether diabetes management strategies that reduce chronic inflammation, such as anti-inflammatory medications or specific diabetes drugs with known immunomodulatory effects, might also influence kidney cancer outcomes in these patients. Drugs like metformin, widely used in T2DM, have shown anti-cancer effects in some studies, and their impact on LST1 and efferocytosis pathways warrants investigation.
For oncologists treating diabetic patients with ccRCC, these results highlight the importance of understanding the tumor immune microenvironment in the context of metabolic comorbidities. The presence of diabetes may fundamentally alter the tumor immune landscape in ways that affect the choice and efficacy of immunotherapy.
Patients and families dealing with both diagnoses can be reassured that research is actively working to understand the biological connection between these conditions and to develop more targeted treatments. The LST1 findings provide a specific, testable hypothesis that can be pursued in clinical biomarker studies.
This study demonstrates the power of single-cell multi-omics analysis for uncovering molecular links between comorbid diseases. By analyzing gene activity at the resolution of individual cells in both T2DM and ccRCC contexts, the researchers could pinpoint a specific gene, LST1, and a specific biological mechanism, efferocytosis, connecting the two conditions.
The validation of LST1 through multiple layers of evidence, including population-level transcriptomics, single-cell analysis, in vivo mouse experiments, and pathway analysis, provides a compelling case that this gene is genuinely important rather than a statistical coincidence.
Future studies should evaluate LST1 protein levels in patient blood samples to assess whether it could serve as a non-invasive circulating biomarker for kidney cancer risk in diabetic patients. Clinical trials investigating LST1-targeting strategies or combination approaches with immunotherapy and diabetes management are natural next steps.
More broadly, this research illustrates a productive approach to studying disease comorbidity: rather than treating diabetes and cancer as separate problems, analyzing them together at the molecular level reveals shared mechanisms that could be targeted to address both conditions simultaneously. This systems-level thinking may be particularly valuable for aging populations where multiple chronic diseases commonly coexist.